65,437 trials
Diffuse Large B-cell Lymphoma
Primary: Response Rate (RR) Achieved After Cycle 6 With RTXM83 Plus CHOP Compared to the RR Obtained With Mabthera® Plus CHOP (R-CHOP) in Patients With DLBCL — 83.6; 82.9; 84.7…
Length of Stay · Postoperative Complications · CRP
Primary: Length of Hospitalization Post-operation — 8.92; 9.67 days — p=0.141
Refractive Errors
Primary: Evaluation of the Most Precise Method for Measuring Post-operative Refraction Following Implantation of the Asymmetric Multifocal LS-313 MF30 — 0.36; 0.27; -0.81; -0.78…
Melanoma
Primary: Best Overall Objective Response Rate (ORR) by Modified "Skin" RECIST — 32.1; 25.0; 25.0 percentage of participants
Stroke
Primary: Change of Cortical Excitability From Baseline to at 4th Weeksand 12th Weeks Training in Motor Evoked Potential at 120% Resting MotorThreshold at Affected Hand — 258.3…
Severe Traumatic Brain Injury
Primary: Fraction of Time That Brain Oxygen Levels Are Below the Critical Threshold of 20 mm Hg . — 0.15; 0.44 Proportion
Burn · Child · Pain
Primary: Acceptability — 68.7; 55.6; 68.7; 85.9 percentage of healthcare responses
Chronic Obstructive Pulmonary Disorder
Primary: Morning Pre-dose Trough FEV1 — 0.072; 0.069; 0.037 Liter
Hypertension
Primary: Feasibility of Retaining Study Participants Through the 3 Month Trial — 20; 21 Participants
COPD
Primary: Change From Baseline in Forced Expiratory Volume in 1 Second (FEV1) — -0.042; 0.006; 0.033; 0.022 Liters
Multiple Myeloma
Primary: Number of Participants With Serious Adverse Events (SAEs) and Common (>=5%) Non-serious Adverse Events- Part 1 — 1; 1; 4; 4 Participants
Temporomandibular Disorder
Primary: Change From Baseline in Visual Analogic Scale (VAS) for Pain — 4.1; 4.4; 5.2; 3.3 millimeters — p=<0.001
Epithelial Ovarian Cancer · Fallopian Tube Cancer · Primary Peritoneal Cancer
Primary: Overall Survival — 574; 552 days — p=0.923
Healthy
Primary: Number of Subjects Experiencing TEAEs. — 3; 0; 4; 1 participants
Peripheral Neuropathy
Primary: Cycle 1 Sensory Neuropathy Score (Items 31-36, 39, 40 and 48) of the European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire…